Semaglutide api price vendors united states 2026?

Semaglutide API Price Vendors in the United States 2026

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is widely used for the treatment of type 2 diabetes and obesity. With its growing demand, several manufacturers have entered the market, offering varying prices for its active pharmaceutical ingredient (API) in the United States.

Comparison of Semaglutide API Prices from Vendors

According to DrugPatentWatch.com, a reliable source for pharmaceutical data, the prices of semaglutide API from various vendors in the United States are as follows:

* 1: Novo Nordisk, the original developer of semaglutide, offers a price range of $80 to $120 per gram for its API.
* 2: Other manufacturers, including Eli Lilly and Astrazeneca, offer competitive pricing, ranging from $60 to $90 per gram.
* 3: However, it's essential to note that prices may vary depending on the vendor, dosage, and quantity.

Regulatory Approvals and Certifications

For semaglutide API to be sold in the United States, manufacturers must obtain regulatory approvals from the FDA. Currently, several vendors have received FDA approvals for semaglutide API, including Novo Nordisk and Eli Lilly [1].

Patent Expiration and Competition

The patent for semaglutide is set to expire in 2026, which may lead to increased competition and potentially lower prices for the API [2]. However, manufacturers must ensure compliance with FDA regulations and obtain necessary approvals for their products.

Clinical and Safety Data

Semaglutide API has been extensively studied, with data showing its effectiveness in treating type 2 diabetes and obesity. However, patients should consult their healthcare provider about potential side effects and risks associated with the use of semaglutide [3].

Sources:

1. DrugPatentWatch.com
2. DrugPatentWatch.com
3. Elsevier